Healaflow
PreclinicalBiologic
Healaflow is one of 8 biologic programs targeting Rhegmatogenous Retinal Detachment. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Rhegmatogenous Retinal Detachment
#DrugCompanyPhaseTrials
1Actigall
AbbVieApproved
Colcrys
Alnylam PharmaceuticalsPhase 3
Denufosol Tetrasodium (INS37217)
Merck & Co.Phase 2
Ursodeoxycholic Acid
Daewoong Pharmaceutical Co. LTD.Phase 1
Intravitreal Topotecan
UUnity Health Toronto
Phase 2
ONL1204
OONL Therapeutics
Phase 1
Healaflow
TTianjin Medical University Eye Hospital
Preclinical
Sulfur Hexafluoride
TTurku University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Healaflow. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details